Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data.

Wednesday’s business headlines INDIANAPOLIS (WISH) — Here is a look at Wednesday’s business headlines with Jane ...

CPP sells products globally through a portfolio of leading brands ... today announced that the data from its phase 1/1b clinical trial of IMU-856, an... at 05:00 AMGEN PROVIDES STATEMENT ON MARITIDE ...

The South African Health Products Regulatory Authority (Sahpra ... Other pharmaceutical players such as Roche, Amgen, Pfizer, ...

R-Car Open Access (RoX) Platform Available for SDV Development Renesas' latest R-Car X5H and all future Gen 5 products are designed to accelerate ... Johnson aims to drive innovation in... at 05:00 ...

AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time ...

Visa said on Tuesday it was rolling out a flexible payments feature in the U.S. and the United Arab Emirates, as it looks to ...

and held various financial and strategic management positions at publicly traded biotechnology companies including Dendreon and Amgen. Ms. Eastland is an independent director of Dynavax Technologies ...

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Corlanor Tablets, 5 mg and 7.5 mg ...

Visier, a leader in workforce AI solutions, announced that it has once again secured the top spot for both vendor ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

Amgen on Wednesday sought to allay concerns that its MariTide, investigational weight-loss shot could be linked to a loss of bone mineral density. Amgen shares fell more than 7% on Tuesday after a ...